Hidradenitis Suppurativa (HS)
Conditions
Keywords
Laser Therapy, Antibodies, Bispecific
Brief summary
The goal of this clinical trial is to learn if combining an IL-17A/F monoclonal antibody with non-ablative fractional laser therapy works and is safe in patients with mild to moderate hidradenitis suppurativa (HS). The main questions it aims to answer are: Does the combination treatment reduce HS symptoms compared to before treatment? What are the main side effects of this combination treatment? Researchers will compare how participants feel and look after treatment to their own condition before treatment. Participants will: Get the combined treatment once every 4 weeks for 16 weeks Give skin and blood samples before the first treatment and at the last treatment visit Have a final check-up 8 weeks after the last treatment
Interventions
COMBINATION_PRODUCTIL-17A/F mAb + NAFL
Bimekizumab 120 mg + NAFL (1565 nm)
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients voluntarily participate in the study and sign the informed consent form. 2. Male or female participants aged ≥ 18 years (at the time of signing the informed consent form). 3. Patients with mild to moderate hidradenitis suppurativa: Hurley stage I or II. 4. Participants have stable disease at screening and baseline, with lesions in ≥ 1 anatomical region and a total abscess and inflammatory nodule (AN) count ≥ 3. 5. Participants must have intolerance, contraindication, or inadequate response to oral antibiotic treatment for HS for at least 3 months, or have relapsed after stopping such treatment. 6. Have a basic understanding of the study purpose, the intervention, and possible side effects, and voluntarily sign the informed consent form in accordance with the spirit of the Declaration of Helsinki. 7. Agree to receive regular treatment, attend follow-up visits, and undergo the required examinations and tests as specified in the clinical study protocol.
Exclusion criteria
1. Known allergy to the study drug or its excipients. 2. Prior use of biologics or small molecule targeted agents. 3. Presence of tunnels on ultrasound at baseline; diagnosed with inflammatory diseases other than HS; history of chronic or recurrent infections; history of malignancy. 4. History of drug abuse, suicide attempt, or psychiatric disorders. 5. Participated in another clinical trial within the past 3 months. 6. Pregnant or breastfeeding women, or those planning to become pregnant during the study period. 7. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for inclusion. 8. Systemic use of corticosteroids within the past 4 weeks, or topical use within the past 2 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Achieving HiSCR (Hidradenitis Suppurativa Clinical Response) at Week 16 | From enrollment to the end of treatment at 16 weeks | HiSCR is defined as at least a 50% reduction from baseline in total abscess and inflammatory nodule count (AN count) and no increase from baseline in abscess or draining tunnel (fistula/sinus tract) count. |
Countries
China
Contacts
CONTACTJiaqi Chen
Outcome results
None listed